Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
Stanford University
ClinicalTrials.gov Identifier:
NCT01556828
First received: March 14, 2012
Last updated: June 22, 2016
Last verified: June 2016
  Purpose
The goal of this study is to identify genetic changes associated with the initiation, progression, and treatment response of response of cutaneous and hematologic disorders using recently developed high-throughput sequencing technologies. The improved understanding of the genetic changes associated with cutaneous and hematologic disorders may lead to improved diagnostic, prognostic and therapeutic options for these disorders.

Condition
Cutaneous Lymphoma
Other Skin Disorders
Mycosis Fungoides
Cutaneous T-cell Lymphoma

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing

Resource links provided by NLM:


Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Number of mutations [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    Identify mutations, changes in DNA copy number, structural rearrangements, or altered coding and non-coding RNA expression


Biospecimen Retention:   Samples With DNA
whole blood tissue

Enrollment: 70
Study Start Date: June 2011
Study Completion Date: June 2014
Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Eligible subjects will be identified and recruited by referral from that individual's treating physician, mainly Stanford-affiliated dermatologists, oncologists, and hematologists.
Criteria

Inclusion Criteria:

  • 18 years of age or older
  • Patient meets the clinical and/or pathologic criteria for the cutaneous or hematologic disorder being examined.
  • Patient is willing to provide skin biopsies and five 10 mL tubes of peripheral blood.

Exclusion Criteria:

- Less than 18 years of age

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01556828

Locations
United States, California
Stanford University, School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Paul Khavari, MD Stanford University
  More Information

Responsible Party: Stanford University
ClinicalTrials.gov Identifier: NCT01556828     History of Changes
Other Study ID Numbers: LYMNHL0091  SU-03142012-9329  21750 
Study First Received: March 14, 2012
Last Updated: June 22, 2016
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Lymphoma
Disease
Lymphoma, T-Cell
Mycoses
Mycosis Fungoides
Lymphoma, T-Cell, Cutaneous
Hematologic Diseases
Skin Diseases
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Pathologic Processes
Lymphoma, Non-Hodgkin

ClinicalTrials.gov processed this record on December 06, 2016